Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin
- 1 September 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 40 (1) , 41-46
- https://doi.org/10.1097/01.qai.0000174930.64145.a9
Abstract
To evaluate treatment outcome of acute hepatitis C virus (HCV) in HIV-positive individuals. Open-label, prospective study conducted in London, January 1997-December 2003. Patients in whom acute HCV infection had been diagnosed had sequential HCV RNA levels measured at 0, 4, 12, 24, 32, and 48 weeks. If HCV RNA positive at 12 weeks, patients were offered pegylated interferon α-2b 1.5 μg/kg/wk and ribavirin 800-1200 mg/d for 24 weeks. Patients with increasing HCV RNA titers were offered treatment earlier. Fifty male homosexuals with a mean age 37 years were identified: 44 from abnormal liver function test results, 4 from sexual contact with an HCV-positive partner, and 2 at HIV seroconversion. Overall, 12 individuals became HCV RNA negative spontaneously. This was significantly associated with high baseline median CD4+ count (P = 0.029), CD4+ count >500 cells/mm3 (P = 0.017), and lower HCV RNA titers (P = 0.017). Only 27 patients accepted treatment, 16 (59%) of whom reached sustained virologic response. This was associated with higher peak mean alanine aminotransferase (P < 0.001) and higher baseline CD4% (P = 0.041). Sustained virologic response rates in HIV-positive patients treated for acute HCV infection are lower than in HIV-negative subjects. Because a high percentage of individuals seroconvert spontaneously, treatment should be delayed until after 12 weeks.Keywords
This publication has 30 references indexed in Scilit:
- Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?Sexually Transmitted Infections, 2004
- Influence of Coinfection with Hepatitis C Virus on Morbidity and Mortality Due to Human Immunodeficiency Virus Infection in the Era of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2003
- Hepatitis C and Progression of HIV DiseaseJAMA, 2002
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- TREATMENT OF HEPATITIS C VIRUS AND HIV CO-INFECTIONSClinics in Liver Disease, 2001
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001
- Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyThe Lancet, 2000
- The Natural History of Hepatitis C Virus InfectionJAMA, 2000
- Hepatitis C Virus Is Related to Progressive Liver Disease in Human Immunodeficiency Virus–Positive Hemophiliacs and Should Be Treated as an Opportunistic InfectionThe Journal of Infectious Diseases, 1999
- Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis CThe Lancet, 1997